Project Description:
The European Training Network named ROPES (ROle of EPitranscriptomics in DiseasES) has been granted in the framework of the Horizon 2020 Marie Skłodowska-Curie Action for Innovative Training Network (ITN).
The project is coordinated by the University of Trento (CIBIO) and it involves ten European laboratories and one biotech company from nine different countries, including: the Medical University of Wien (Austria), the University of Lausanne (Switzerland), the International Institute of Molecular and Cell Biology (Poland), the Umea University (Sweden), the German Cancer Research Center DKFZ (Germany), il Consiglio Nazionale delle Ricerche (Italy), the Centre for Genomic Regulation (Spain), CEITEC- University of Masaryk (Czech Republic), IMMAGINA Biotechnology Srl (Italy), Free University of Bruxelles (Belgium).
The project aims to unravel the role of epitranscriptomics in diseases and to exploit it for novel therapies. ROPES, awarded with 3M € from the European Commission, started on December 2020, and will recruit Early Stage Researchers to perform innovative research projects in cooperation with leading universities in Europe and the United States of America.
The focus of this PhD program is to develop molecules endowed with the ability to inhibit the signaling mediated by the YTH proteins when binding their ligand, N6-methyladenosine (m6a), and to test these molecules in at least one relevant disease condition for a potential therapeutic effect in an in vivo model. This first condition will be the developmental tumor neuroblastoma. On the best molecule candidate, the study will also establish the basis for the action with respect to possible selectivity amongst the 5 YTH human proteins and their physiological role. The ESR (Early-stage Researcher) will be contractually employed for 36 months by the University of Trento and will be covered under the Italian social security scheme. The research will be carried out as a doctoral candidate within the PhD programme in Biomolecular Sciences. Therefore, in addition to their individual scientific projects, the successful candidate will benefit from further continuing education, which includes internships and secondments, a variety of training modules, as well as courses on transferable skills and active participation in workshops and conferences.
Benefits:
- Successful candidates will receive a salary/fellowship in accordance with the MSCA regulations for Early Stage Researchers. The exact salary/fellowship will be confirmed upon appointment and will amount Euro 3.270,00 total costs/month corrected by the country-specific coefficient (living allowance).
- The salary/fellowship includes a mobility allowance and a family allowance (if applicable).
- Funding is guaranteed for 36 months.
- In addition to their individual scientific projects, the successful candidates will benefit from further continuing education, which includes internships and secondments, a variety of training modules, as well as courses on transferable skills and active participation in workshops and conferences.
Eligibility criteria:
Candidates must demonstrate eligibility according to the Marie Sklodowska-Curie Actions eligibility requirements as follows:
- Researcher status: Early-Stage Researchers (ESRs) are young researchers who, at the date of recruitment, are in the first four years (full-time equivalent research experience) of their research careers and have not been awarded a doctoral degree.
- Nationality: Applicant ESRs can be of any nationality.
- Mobility requirements: Applicant ESRs must not have resided or carried out their main activity (work, studies, etc.) in the country of the recruiting beneficiary for more than 12 months in the 3 years immediately prior to the date of recruitment.
Continue with Facebook
